LABORATORY REPORT

Redcliffe labs

Patient Name	: **Mr MR.DUMMY**		
DOB/Age/Gender	: 23 Y/Male	Sample Collected	: Apr 26, 2024, 01:00 PM
Patient ID / UHID	: 8052176/RCL7248623	Report Date	: May 25, 2024, 01:30 PM.
Referred By	: Dr. Dr. X	Barcode No	: SI485049
Sample Type	: Serum	Report Status	: Final Report

Test Description	Value(s)	Unit(s)	Reference Range

Anti Phospholipase A2 Receptor Antibody (PLA2R)

Anti Phospholipase A2 Recepto *(EIA)*	11	RU/mL	0 - 14

Interpretation:

Note:

A diagnosis of primary or secondary Membranous Nephropathy should not be made on a single test result. The clinical symptoms, results on physical examination, and laboratory tests when appropriate, should always be taken into account when considering the diagnosis of Primary versus Secondary Membranous Nephropathy.

2. Absence of circulating PLA2R antibodies does not rule out a diagnosis of Primary Membranous Nephropathy

3. Test conducted on serum.

Interpretation :

RESULTS IN RU/mL	REMARKS
<14	Negative
14-20	Borderline
>20	Positive

Comment :

Autoantibodies of class IgG against Phospholipase A2 receptors are highly specific for the diagnosis of Primary Membranous Nephropathy (PMN) and can be detected in the serum of up to 70-75% of patients. It has been reported that during the clinical course of PMN, the degree of proteinuria and declining renal function are significantly associated with the serum PLA2R antibody level. It has been suggested that serum levels of PLA2R antibody are a potentially useful marker for the prediction of diagnosis and for monitoring the treatment response in PMN. Patients with chronic kidney disease (CKD) awaiting kidney transplantation, detection of high levels of PLA2R antibodies is indicative of disease recurrence.

Clinical Use :

1. To distinguish Primary from Secondary Membranous Nephropathy
2. To monitor therapy in patients of PMN

*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Dr. Dummy

Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI

Processing Lab :-

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.

2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.

3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.

4. This report shall not be deemed valid or admissible for any medico-legal purposes.

5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.